title: Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
abstract: OBJECTIVE
  The objectives of this double-blind study were to assess the tolerability and i.v. tyramine pressor response during combined treatment with moclobemide and selegiline.
  
  
  METHODS
  Two parallel groups of 12 healthy male and female subjects were treated with 200 mg moclobemide or 5 mg selegiline b.d. for 14 days. On Day 7, selegiline or moclobemide was added to the other treatment. IV tyramine pressor tests were conducted at baseline and at steady state during mono- and combined treatment.
  
  
  RESULTS
  Treatment with moclobemide and selegiline alone was well tolerated, whereas combined treatment led to a slight increase in adverse events. Tyramine pressor sensitivity during moclobemide, selegiline and moclobemide + selegiline treatment was enhanced, on average, by 2.4-, 1.3- and 8.4-times, respectively.
  
  
  CONCLUSIONS
  Although combined treatment with moclobemide and selegiline was well tolerated, the supra-additive potentiation of the tyramine pressor effects means that dietary restriction of tyramine intake will be necessary during such combination therapy.
authors.affiliation: Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Korn
authors.forename: B
authors.initials: B
authors.lastname: Wagner
authors.forename: E
authors.initials: E
authors.lastname: Moritz
authors.forename: J
authors.initials: J
authors.lastname: Dingemanse
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology*; D000328:Adult; D000704:Analysis of Variance; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D018565:Food-Drug Interactions; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007275:Injections, Intravenous; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*; D014439:Tyramine / Q000494:pharmacology*
chemical_list: D018663:Adrenergic Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D020912:Moclobemide; D014439:Tyramine